Antioxidants and Redox Signaling · 2021 · 18 citations · 44 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyInflammationMolecular PharmacologyAnti-inflammatory PharmacologyGastrointestinal InflammationGastrointestinal PharmacologyGastrointestinal ToxicityInflammation PharmacologyMolecular Mechanisms Of ToxicityAnti-inflammatory TherapeuticsDrug-induced Mucosal InjuryGastrointestinal MucosaGastroprotective AgentsGut Microbiome AlterationsMucosal ProtectionNonsteroidal Anti-inflammatory Drug PharmacologyNonsteroidal Anti-inflammatory Drug Safety
Aims: Nonsteroidal anti-inflammatory drugs, including ketoprofen, induce adverse effects within the gastrointestinal (GI)-tract. Hydrogen sulfide (H 2 S) is an antioxidative gaseous mediator contributing to GI-protection. We aimed to evaluate the GI safety of a novel H 2 S-releasing derivative of ketoprofen (ATB-352) versus classic ketoprofen and the molecular mechanisms of their activity after chronic treatment in experimental animal models. Results: Ketoprofen (10 mg/kg/day) administered intragastrically for 7 days in contrast with ATB-352 (14 mg/kg/day) reduced mucosal H 2 S content inducing GI damage with significantly increased injury score, altered intestinal microbiome profile, and modulation of more than 50% of 36 investigated molecular sensors ( e.g ., mammalian target of rapamycin or suppressor of cytokine signaling 3 [SOCS3]). Polypharmacy with aspirin (10 mg/kg/day) enhanced ketoprofen toxicity not affecting GI safety of ATB-352. Omeprazole (20 mg/kg/day) decreased ketoprofen-induced injury to the level of ATB-352 alone. Both compounds combined or not with aspirin or omeprazole maintained the ability to inhibit cyclooxygenase (COX) activity manifested by decreased prostaglandin production. Innovation and Conclusions: Ketoprofen-induced H 2 S-production decrease and intestinal microbiome profile alterations lead to GI toxicity observed on macro-/microscopic and molecular levels. Ketoprofen but not ATB-352 requires concomitant treatment with omeprazole to eliminate GI adverse effects. ATB-352 applied alone or in a polypharmacy setting with aspirin effectively inhibited COX and maintained GI safety due to H 2 S-release. Neither compound affected DNA oxidation in the GI mucosa, but ATB-352 had lower impact on molecular oxidative/inflammatory response pathways and intestinal microbiome. The GI safety of ATB-352 could be due to the involvement of heme oxygenase 1 and SOCS3 pathway activation. Antioxid. Redox Signal . 36, 189–210.
44
Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
Michiru Nishita, Seung‐Yeol Park, Tadashi Nishio et al. · Scientific Reports · 2017 · 16.1K citations · Full text
Andrew D. Fernandes, Jennifer Reid, Jean M. Macklaim et al. · Microbiome · 2014 · 1.4K citations · Full text
Life Sciences, Biology, Microbiology +16